alexa Intraductal Carcinoma of the Prostate Diagnosed by Multi-Parametric Prostate Magnetic Resonance Imaging (MRI) and MRI/Ultrasound Fusion-Guided Biopsy | Open Access Journals
ISSN: 2090-4924
International Journal of Biomedical Data Mining
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Intraductal Carcinoma of the Prostate Diagnosed by Multi-Parametric Prostate Magnetic Resonance Imaging (MRI) and MRI/Ultrasound Fusion-Guided Biopsy

Ardeshir R Rastinehad1,3*, Mathew Fakhoury1, Simpa S Salami1, Oksana Yaskiv2, Omid Rofeim1, Robert Villani3, Eran Ben-Levi3

1The Arthur Smith Institute for Urology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY 11042, USA

2Department of Pathology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY 11042, USA

3Department of Interventional Radiology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY 11042, USA

Corresponding Author:
Ardeshir R Rastinehad
D.O, The Arthur Smith Institute for Urology
Hofstra North Shore-LIJ School of Medicine
450 Lakeville Rd, Suite M-41
New Hyde Park, NY 11040, USA
Tel: 516-734-8500
Fax: 516-734-8537
E-mail: [email protected]

Received date: March 06, 2014; Accepted date: October 14, 2014; Published date: February 05, 2015

Citation: Rastinehad AR, Fakhoury M, Salami SS, Yaskiv O, Rofeim O, et al. (2015) Intraductal Carcinoma of the Prostate Diagnosed by Multi-Parametric Prostate Magnetic Resonance Imaging (MRI) and MRI/Ultrasound Fusion-Guided Biopsy. Int J Biomed Data Min 3:106. doi: 10.4172/2090-4924.1000106

Copyright: ©2015 Rastinehad AR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at International Journal of Biomedical Data Mining

Abstract

Intraductal carcinoma of the prostate (IDC-P) is an aggressive form of prostate cancer (CaP) with clinical and pathological features distinguishing it from high-grade prostatic intraepithelial neoplasia (HG-PIN). IDC-P is characterized by a high volume and high-grade disease, with an aggressive behavior. We present the case of a 63-year-old male with diagnostic MRI imaging indicative of IDC-P. To our knowledge, this is the first reported case of IDC-P identified with multi-parametric MRI.

Keywords

Prostate imaging; Prostate fusion biopsy

Introduction

Although, the term “intraductal carcinoma of the prostate” (IDC-P) was first used by Rhamy [1], McNeak and Yemoto, were the first to delineate IDC-P as a distinct biological entity with definable histological and clinical features [2]. IDC-P is defined as a proliferation of malignant prostate adenocarcinoma cells distending or completely spanning the lumen of pre-existing prostatic ducts and acini, with at least focal preservation of basal cells. Watts et al. estimated the incidence of IDC-P to 2.8% in prostate biopsies [3].

Histological criteria for the diagnosis of IDC-P include solid; dense cribriform (>50% cellularity of the lumen); trabecular/micropapillary; and loose cribriform intraductal proliferation of malignant cells. The latter two growth patterns share much similarity with HGPIN. In these instances, additional diagnostic criteria, such as marked nuclear pleomorphism (nuclear enlargement > 6x normal nuclei), and nonfocal comedonecrosis (> 1 duct showing comedonecrosis) are criteria needed to differentiate it from HGPIN.

The presence of IDC-P in biopsy specimens is regarded as a marker of aggressive disease and definitive therapy is often recommended even in the absence of invasive adenocarcinoma [4-6]. The presence of IDC-P in radical prostatectomy (RP) specimens is often associated with high Gleason Score (Gleason 4 or 5), larger tumor volume, greater probability of extraprostatic extension, positive surgical margin and high biochemical recurrence rate [6,7]. The use of preoperative imaging for diagnosis has never been described. Herein, we report a case of IDC-P diagnosed with multiparametric (MP-MRI) with endorectal coil.

Case Presentation

A 63-year-old Caucasian male with no significant comorbidities presented with a history of elevated serum PSA levels (4 to 12.17 ng/ mL), PSA velocity of 14.51 ng/mL/year; PSA doubling time of 4.51 months; and a total of 5 previous negative prostate biopsies. One previous biopsy showed extensive HG-PIN. Of note, his father was diagnosed with Prostate Cancer (CaP) at age 75, resulting in his death. Digital rectal examination revealed a benign gland.

He underwent MP-MRI of the prostate at an outside institution that demonstrated an intermediate lesion in the left prostatic lobe consistent with HG-PIN or prostatitis; hence no prostate biopsy was done at the time. As shown in Figure 1, MP-MRI (See Appendix A for MRI Parameters) done two years later at our institution showed marked central gland hyperplasia with mass effect on the bladder (Table 1). The peripheral zone was diffusely heterogeneous with two focal suspicious lesions. The first lesion in the right mid gland measured 7×6×9 mm and was triple positive i.e. low signal and focal on T2; low signal with an Apparent Diffusion Coefficient (ADC) value of 794×10-6 mm2s−1on Diffusion-Weighted Imaging (DWI); and on Dynamic Contrast Enhancement (DCE), showed avid enhancement with a type 3 curve. The second lesion in the left mid gland peripheral zone was also triple positive with focal low T2 signal; ADC value of 794×10-6 mm2s−1; and a type 3 enhancement curve. The b-2000 DWI had diffuse high signal throughout the peripheral zone. There was no evidence of extraprostatic extension (EPE).

biomedical-data-mining-3T-Multi-Parametric-MRI

Figure 1: 3T Multi-Parametric MRI of the Prostate with an endorectal coil. The largest lesion is denoted by the yellow arrow. A. T2 weighted axial image showing bilateral heterogeneous low signal lesions within the gland. B. ADC map with bilateral restricted areas within the peripheral zone (largest arrow). C. DCE with bilateral enhancement a ktrans map. D. T2 coronal image showing diffuse heterogenous low signal. E. b-2000 DWI image with bilateral high signal throughout the gland. F. DCE contrast enhancement type III curve.

  sag t2 ax vibe cor t2 axial t2 dwi 5 b-values dwi b-2000 dce whole pelv
# slices 30 30 30 30 30 30 30 88
sithk 3.0mm 3.0mm 3.0mm 3.0mm 3.0mm 3.0mm 3.0mm 3.0mm
gap 0 0 0 0 0 0 0 20%
TR 4150ms 3.63ms 4150ms 4000ms 12,600ms 12,600ms 3.00ms 3.92ms
TE 121ms 1.74ms 121ms 120ms 96ms 96ms 0.94ms 1.39ms
FOV 200mm 272mm 200mm 140mm 260mm 260mm 250mm 380mm
pFOV 100% 93.80% 100% 100% 71.6% 71.6% 100% 81.3%
AVG 2 1 2 2 2 2 1 1
CONCAT 2 1 2 2 1 1 1 1
DIST CORR On On On On On On On On
prescan normalize On On On B1 filter On On On On
pOS 50% 50% 50% 75% 50% 50% 50% 0%
Phenc H to F Rt to Lt Rt to Lt Rt to Lt Rt to Lt Rt to Lt Rt to Lt Rt to Lt
flip angle 150 9 150 132     12 10
fat suppr None None None None SPAIR SPAIR None Q-fat sat
base res. 384 320 384 384 162 162 128 320
phresol 95% 75% 80% 80% 70% 70% 100% 70%
ph partial fourler Off Off Off Off 6/8 6/8 7/8 Off
PAT MODE GRAPPA GRAPPA GRAPPA GRAPPA GRAPPA GRAPPA GRAPPA GRAPPA
ACCEL FACTOR 2 2 2 2 2 2 2 2
Multi-slice mode Interleave Sequential Interleave Interleave Interleave Interleave Sequential Sequential
posit mode Isocenter Isocenter Isocenter Isocenter Isocenter Isocenter Isocenter Isocenter
plane sagittal axial coronal axial axial axial axial axial
Direct rt to lt ft to head A to P ft to head ft to head ft to head ft to head ft to head
Turbo Factor 23   23 20        
Echo Trains 121ms   11 14        
Allowed Delay 60s 60s 60s 60s     60s 60s
BWTH 224Hz/Px 870Hz/Px 224Hz/Px 233Hz/Px 1470Hz/Px 1470Hz/Px 1000Hz/Px 400Hz/Px
si OS   33.30%         33.30% 9.10%
b-values         0, 50, 500, 1000, 1500s/mm 0, 2000s/mm    
EPI factor         81 81    
Diff Direct         3 3    
Diff Mode         3-scan trace 3-scan trace    
Elliptical scanning Off Off Off Off Off Off On Off
Slice partial fourler               65%

Table 1: MRI Parameters.

The patient underwent MRI/Transrectal Ultrasound (TRUS) Fusion-Guided prostate biopsy (UroNav, Philips Healthcare, Gainesville FL, USA®) of the two suspicious lesions. A standard 12-core TRUSguided biopsy was then performed. No hypoechoic area suspicious for cancer was identified on TRUS. MRI/TRUS fusion-guided prostate biopsy of the two suspicious lesions detected IDC-P, the largest with a diameter of 10 mm. The first diagnostic biopsy performed showed extensive IDC-P component, present in 16 out of 17 biopsy cores. A single focus of Gleason Score 3+3 adenocarcinoma was identified in one core (1 mm). Pathological diagnosis in this case was challenging because the micropapillary and tufting growth pattern of IDC-P are difficult to differentiate from HGPIN, and therefore require additional diagnostic criteria to confirm the diagnosis. These include nuclear pleomorphism and immunohistochemical staining highlighting basal cells, such as p63, and high molecular weight cytokeratin (HMWCK). Positive staining for the above markers supports the intraductal nature of the lesion. Additionally, alpha-methylacyl-CoA racemase (AMACR or P504S), a marker preferentially expressed in CaP also stained positive.

The patient underwent radical prostatectomy and bilateral pelvic lymph node dissection. Histological examination of the prostate showed a predominantly micropapillary/tufting growth pattern with rare ducts showing loose cribriform morphology. The presence of marked nuclear pleomorphism, non-focal comedonecrosis confirmed the diagnosis of IDC-P. Additionally, conventional/acinar Gleason Score 3+4 invasive adenocarcinoma of the prostate were identified. Intraductal and invasive components of the carcinoma were confined to the prostate gland, rendering a pathological stage pT2 (Figure 2a and b). A total of 3 pelvic lymph nodes removed were negative for malignancy.

biomedical-data-mining-Intraductal-carcinoma-prostate

Figure 2: 2a) Intraductal carcinoma of the prostate, showing pre-existing prostatic dust, lined by basal cells (blue arrow) and expended by highly pleomorphic cells (black arrow) forming loose cribriform structures. Central comedonecrosis is also present (red arrow). 2b). Intraductal carcinoma of the prostate with preserved basal cells layer (blue arrow) and intraluminal highly pleomorphic cells (black arrow) with tufted architecture.

Discussion

Several studies have demonstrated that IDC-P is an aggressive disease with poor prognosis [7]. Since IDC-P rarely presents as an isolated finding, a diagnosis of IDC-P on prostate biopsy warrants at least immediate repeat biopsy and preferably definitive surgical therapy [4]. The pathological findings in our case, showed extensive IDC-P as well as a focus of invasive carcinoma, prompting definitive surgical intervention. The growing body of literature confirms the importance of reporting IDC-P in biopsy and RP specimens since it is generally associated with an overall poor prognosis. Majority of cases of IDC-P show concomitant high grade (Gleason pattern 4 or 5) and high volume invasive adenocarcinoma. IDC-P associated with low grade (Gleason pattern 3 or less) invasive carcinoma are rare [7].

MP-MRI has been reported to show a predilection for diagnosing high grade CaP, hence IDC-P can be challenging to diagnose when associated with low grade CaP. IDC-P can mimic low grade CaP on T2-weighted MRI, with intermediate to low signal intensity as reported by Schieda et al. [8]. These findings are similar to those observed in our case, in which we presented bilateral low signal (SI 0.39) heterogeneous lesions within the gland on T2-weighted axial image. The ADC map demonstrated restricted areas within the peripheral zone while the DCE showed bilateral enhancement (Figure 1).

Histological features of IDC-P include proliferation of malignant cells within the native prostatic acini and ducts with at least partial preservation of their basal layer.7 McNeal et al. concluded that IDC-P has precise histological criteria with unique biological and clinical significance. The main architectural patterns of growth include solid; dense cribriform (>50% cellularity of the lumen); trabecular/ micropapillary; and loose cribriform morphology. Neoplastic cells in IDC-P also show significant nuclear pleomorphism (nuclear enlargement up to 6 times that of adjacent non-neoplastic nuclei). Although, comedonecrosis is an important diagnostic feature of IDC-P, it may not always be present [9].

Cohen et al. have introduced a set of five major criteria for diagnosing IDC-P [10] and include 1) large-caliber glands that are more than twice the diameter of normal peripheral zone gland structures; 2) preserved basal cell layer identified with basal cell markers (34βE12, p63) [11,12]; 3) glands filled with cytological malignant cells (in contrast to those of HG-PIN); 4) the cells always span the gland lumen; and 5) central comedonecrosis. The first 4 major criteria listed are always present in IDC-P. Although central comedonecrosis is not always present, it is a common finding in IDC-P and it is never a feature of HG-PIN. The case presented above met all five of the Cohen criteria. Although comedonecrosis was not identified on prostate biopsy, it was present on subsequent RP specimen.

At the molecular level, evidence supports the distinction of IDC-P amongst its counterparts, through the loss of heterozygosity (LOH) for 12 polymorphic microsatellite markers, known to be frequently lost in CaP. A distinction was made between LOH amounts in HG-PIN, IDC-P, and invasive carcinoma. Study quantifications showed that LOH was absent in Gleason grade 3 cancers, present in 29% of Gleason grade 4 cancers, and commonly found in 60% of IDC-P cases [9].

Clinically, IDC-P is associated with relatively decreased progression free survival [9,12,13] IDC-P found in prostate biopsies is not common, however when it is identified, involvement with high grade and high volume CaP is very likely. Poor prognostic factors such as EPE and SVI were identified in 67% and 44% of patients respectively [3]. Interestingly, Cohen et al. and associates reported that serum PSA levels correlate with tumor volume only when IDC-P was not present in biopsy. These findings suggest that prostate biopsy identified IDC-P counteracts normal and predictive parameters, including PSA and Gleason score. Of note, no nomogram takes into account the presence of IDC-P as masking a high grade or high volume tumor with low PSA. Therefore, IDC-P in biopsies should be reported even when it is associated with high-grade cancer as it may provide prognostic value in management.

Conclusion

IDC-P is a distinct and aggressive clinic pathologic entity. It is critical to recognize and report IDC-P in prostate specimens in order to improve patient selection for management. IDC-P is strongly associated with aggressive CaP with a high Gleason grade and large tumor volume requiring immediate intervention. We report on a patient with IDC-P identified for the first time by multi-parametric MRI imaging.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 11940
  • [From(publication date):
    December-2014 - Nov 20, 2017]
  • Breakdown by view type
  • HTML page views : 8128
  • PDF downloads : 3812
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords